In this edition, germline testing 'should be considered' for all patients with lung cancer; phase 3 trial of canakinumab misses endpoint; sexual dysfunction common among women with lung cancer, and more. Read the full coverage here: Germline testing 'should be considered' for all patients with lung cancer, data suggest Phase 3 trial of canakinumab for non-small cell lung cancer misses endpoint Sexual dysfunction common among women with lung cancer Younger patients with lung cancer more likely to have advanced disease at diagnosis Sotorasib extends PFS in lung cancer subset References: Florez N, et al. Abstract MA14. Presented at: International Association for the Study of Lung Cancer World Conference on Lung Cancer (hybrid meeting); Aug. 6-9, 2022; Vienna. Potter A, et al. Abstract OA05. Presented at: International Association for the Study of Lung Cancer World Conference on Lung Cancer (hybrid meeting); Aug. 6-9, 2022; Vienna. Press Release Press Release Sorscher S, et al. Abstract 388570. Presented at: ASCO Plenary Series (virtual); Aug. 16, 2022.

Ver todos los episodios